Lotus Pharmaceuticals, Inc (LTUS) Fair Value & Analysis
Financial Services · US · Market cap $10.3M
Lotus Pharmaceuticals, Inc
LTUS · US
Fair value as of: Aug 19, 2026
From 1 valuation models · updated today
Share price +26.7% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price is below even our cautious bear case ($0.0040). The market is more pessimistic than our downside scenario.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range $0.0006 – $0.0599 · the $0.0038 price screens below the $0.0040 fair value. Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Lotus Pharmaceuticals, Inc (LTUS) currently trades at $0.0038, while our model-based Fair Value estimate is $0.0040, implying the stock looks roughly 5.3% fairly valued today. The Quality Score stands at 54/100 (solid quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Lotus Pharmaceuticals, Inc generated revenue of $71.4M at a net margin of 2.4%. Revenue grew 4.0% year over year. It earns a return on equity of 1.8%. Fundamentals as of Aug 19, 2026
The share trades about 66% below its 52-week high and 52% above its 52-week low, currently below its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -61% fair-value upside, at 5%, LTUS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when LTUS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company was formerly known as S.E. Asia Trading, Inc. and changed its name to Lotus Pharmaceuticals, Inc. in December 2006. Lotus Pharmaceuticals, Inc.
Full company description
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company was formerly known as S.E. Asia Trading, Inc. and changed its name to Lotus Pharmaceuticals, Inc. in December 2006. Lotus Pharmaceuticals, Inc. is based in Irvine, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2006 – FY2025 · reported fiscal years
Lotus Pharmaceuticals, Inc reported revenue of $72.7M in FY2010 versus $36.2M in FY2006, a compound +19.0%/yr. Reported net income was −$29.0K in FY2025.
Watch LTUS: get an alert when its fair value changes →
Peer Group
Shell Companies · 91 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Shell Companies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Shell Companies stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Coca-Cola Company COLA | C$30.34 | C$10.62 | -65% |
| Lionheart III Corp LION | $11.73 | $18.15 | +55% |
| Agriculture & Natural Solutions Acquisition Corporation ANSC | $11.46 | $4.13 | -64% |
| AA Mission Acquisition Corp AAM | $0.0390 | $0.0394 | +1% |
| GP-Act III Acquisition Corp GPAT | $11.16 | $4.30 | -61% |
| Metals Acquisition Corp MTAL | $10.24 | $20.48 | +100% |
| Berto Acquisition Corp TACO | $10.45 | $2.73 | -74% |
| Axiom Intelligence Acquisition Corp AXIN | $10.29 | $1.46 | -86% |
| Bold Eagle Acquisition Corp BEAG | $10.75 | $4.00 | -63% |
| Lionheart Holdings CUB | $10.88 | $5.06 | -53% |
Compare Lotus Pharmaceuticals, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Lotus Pharmaceuticals, Inc (LTUS) overvalued or undervalued?
What is the fair value of LTUS?
What is the quality score of LTUS?
What is the revenue of Lotus Pharmaceuticals, Inc (LTUS)?
What is the net profit margin of LTUS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Lotus Pharmaceuticals, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.